Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Talia Golan(Sheba Medical Center), Steven Gallinger(Ontario Institute for Cancer Research), David W. Hedley(Ontario Institute for Cancer Research), Efrat Dagan(University of Haifa), Nicholas Devaud(Mount Sinai Hospital), Zaheer Kanji(Virginia Mason Medical Center), Eitan Friedman(University of Pennsylvania), Ruth Gershoni‐Baruch(Technion – Israel Institute of Technology), Dan Aderka(Sheba Medical Center), Brett A. Kaufman(Tel Aviv University), Ron Epelbaum(Rambam Health Care Campus), Shani Paluch–Shimon(Hebrew University of Jerusalem), Spring Holter(Lunenfeld-Tanenbaum Research Institute), Malcolm J. Moore(University Health Network)
Cited by 437
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k